CR20170536A - Derivados de etinilo - Google Patents

Derivados de etinilo

Info

Publication number
CR20170536A
CR20170536A CR20170536A CR20170536A CR20170536A CR 20170536 A CR20170536 A CR 20170536A CR 20170536 A CR20170536 A CR 20170536A CR 20170536 A CR20170536 A CR 20170536A CR 20170536 A CR20170536 A CR 20170536A
Authority
CR
Costa Rica
Prior art keywords
formula
disease
ethylene derivatives
gerd
anxiety
Prior art date
Application number
CR20170536A
Other languages
English (en)
Inventor
Georg Jaeschke
Eric Vieira
Lothar; Lindemann
Antonio Ricci
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CR20170536A publication Critical patent/CR20170536A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C11/00—Aliphatic unsaturated hydrocarbons
    • C07C11/22—Aliphatic unsaturated hydrocarbons containing carbon-to-carbon triple bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a derivados de etinilo de fórmula I I en la que R1 es hidrógeno o F; n es 1 o 2 o una sal de adición de ácido farmacéuticamente de los mismos. Se ha descubierto sorprendentemente que los compuestos de fórmula I son antagonistas del receptor de glutamato metabotrópico (moduladores alostéricos negativos) para su uso en el tratamiento de la ansiedad y dolor, depresión, síndrome de X frágil, trastornos del espectro autista, enfermedad de Parkinson, y enfermedad de reflujo gastroesofágico (ERGE).
CR20170536A 2015-06-03 2016-05-31 Derivados de etinilo CR20170536A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15170401 2015-06-03
PCT/EP2016/062202 WO2016193234A1 (en) 2015-06-03 2016-05-31 Ethynyl derivatives

Publications (1)

Publication Number Publication Date
CR20170536A true CR20170536A (es) 2018-02-01

Family

ID=53276789

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20170536A CR20170536A (es) 2015-06-03 2016-05-31 Derivados de etinilo

Country Status (31)

Country Link
US (2) US11059766B2 (es)
EP (1) EP3303316B1 (es)
JP (1) JP6603334B2 (es)
KR (1) KR102035048B1 (es)
CN (1) CN107849006B (es)
AR (1) AR104842A1 (es)
AU (1) AU2016273751B2 (es)
BR (1) BR112017023894A2 (es)
CA (1) CA2985301A1 (es)
CL (1) CL2017002969A1 (es)
CO (1) CO2017012260A2 (es)
CR (1) CR20170536A (es)
DK (1) DK3303316T3 (es)
ES (1) ES2786673T3 (es)
HK (1) HK1249096A1 (es)
HR (1) HRP20200638T1 (es)
HU (1) HUE048867T2 (es)
IL (1) IL255367B (es)
LT (1) LT3303316T (es)
MA (1) MA42508B1 (es)
MX (1) MX2017015043A (es)
PE (1) PE20180358A1 (es)
PH (1) PH12017502128A1 (es)
PL (1) PL3303316T3 (es)
PT (1) PT3303316T (es)
RS (1) RS60199B1 (es)
RU (1) RU2712633C1 (es)
SI (1) SI3303316T1 (es)
TW (1) TWI589571B (es)
UA (1) UA120309C2 (es)
WO (1) WO2016193234A1 (es)

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3549655A (en) * 1967-12-21 1970-12-22 Dow Chemical Co N-(substituted phenyl) cyclobutanedicarboximides
FI90869C (fi) 1986-11-14 1994-04-11 Tanabe Seiyaku Co Menetelmä lääkeaineena käyttökelpoisten imidatsolidinonijohdannaisten valmistamiseksi
JP3213780B2 (ja) 1993-12-21 2001-10-02 キヤノン株式会社 光学活性化合物、これを含有する液晶組成物、該液晶組成物を用いた液晶素子並びにこれらを用いた表示方法、表示装置
GB9510744D0 (en) 1995-05-26 1995-07-19 Zeneca Ltd Chemical process
JPH09151179A (ja) 1995-11-30 1997-06-10 Canon Inc 光学活性化合物、これを含む液晶組成物、それを有する液晶素子、それらを用いた液晶装置及び表示方法
SK4382001A3 (en) 1998-10-02 2001-08-06 Novartis Ag Mglur5 antagonists for the treatment of pain and anxiety
CA2383524C (en) 1999-08-31 2010-09-28 Merck & Co., Inc. Thiazolyl alkynyl compounds and methods of use thereof
RU2266905C2 (ru) 1999-09-28 2005-12-27 Эйсай Ко., Лтд. Хинуклидиновые соединения, содержащие их лекарственные средства и способы получения хинуклидиновых соединений
WO2002014517A1 (en) 2000-08-11 2002-02-21 Monsanto Technology Llc BROAD-SPECTRUM δ-ENDOTOXINS
US6410728B1 (en) 2000-08-31 2002-06-25 Abbott Laboratories Oxazolidinone chemotherapeutic agents
GB0103045D0 (en) * 2001-02-07 2001-03-21 Novartis Ag Organic Compounds
JP4225787B2 (ja) 2001-03-27 2009-02-18 エーザイ・アール・アンド・ディー・マネジメント株式会社 Ｎ−アリール環状アミン誘導体およびそれを有効成分として含有する医薬
CA2442478C (en) 2001-04-02 2010-02-02 Mark F. Bear Use of group i mglur antagonists in the treatment of fragile x syndrome, autism, mental retardation
WO2004038374A2 (en) 2002-10-24 2004-05-06 Merck & Co., Inc. Alkyne derivatives as tracers for metabotropic glutamate receptor binding
DE10250708A1 (de) 2002-10-31 2004-05-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Alkin-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
ATE445399T1 (de) 2004-03-22 2009-10-15 Lilly Co Eli Pyridyl-derivate und ihre verwendung als mglu5- rezeptorantagonisten
WO2005108370A1 (ja) 2004-04-16 2005-11-17 Ajinomoto Co., Inc. ベンゼン化合物
EP2380889B1 (en) 2004-10-07 2013-06-26 Merck Sharp & Dohme Corp. Thiazolyl MGLUR5 antagonists and methods for their use
WO2006048771A1 (en) 2004-11-04 2006-05-11 Addex Pharmaceuticals Sa Novel tetrazole derivatives as positive allosteric modulators of metabotropic glutamate receptors
GB0510139D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B1
GB0514296D0 (en) 2005-07-12 2005-08-17 Novartis Ag Organic compounds
EP1919890A1 (en) 2005-08-19 2008-05-14 AstraZeneca AB Pyrazolone derivatives for the treatment of tuberculosis
WO2007035823A2 (en) * 2005-09-20 2007-03-29 Molecular Neuroimaging, Llc Partial mglur5 antagonists and methods of use thereof
AU2008259776A1 (en) 2007-06-03 2008-12-11 Vanderbilt University Benzamide mGluR5 positive allosteric modulators and methods of making and using same
US8853392B2 (en) 2007-06-03 2014-10-07 Vanderbilt University Benzamide mGluR5 positive allosteric modulators and methods of making and using same
US8034806B2 (en) 2007-11-02 2011-10-11 Vanderbilt University Bicyclic mGluR5 positive allosteric modulators and methods of making and using same
WO2009098208A1 (en) 2008-02-05 2009-08-13 Neurosearch A/S Novel phenylethynyl derivatives of 8-aza-bicyclo[3.2.1]octane and their use as monoamine neurotransmitter re-uptake inhibitors
WO2010063487A1 (en) 2008-12-05 2010-06-10 Merz Pharma Gmbh & Co. Kgaa Pyrazolopyrimidines, a process for their preparation and their use as medicine
TW201116532A (en) 2009-08-05 2011-05-16 Merz Pharma Gmbh & Co Kgaa Metabotropic glutamate receptor modulators
US8389536B2 (en) 2009-10-27 2013-03-05 Hoffmann-La Roche Inc. Positive allosteric modulators (PAM)
US8586581B2 (en) 2009-12-17 2013-11-19 Hoffmann-La Roche Inc Ethynyl compounds useful for treatment of CNS disorders
US8420661B2 (en) 2010-04-13 2013-04-16 Hoffmann-La Roche Inc. Arylethynyl derivatives
NZ603868A (en) 2010-07-09 2014-08-29 Recordati Ireland Ltd Novel spiroheterocyclic compounds as mglu5 antagonists
WO2012015024A1 (ja) 2010-07-29 2012-02-02 大正製薬株式会社 エチニル－ピラゾール誘導体
US8691821B2 (en) 2010-11-11 2014-04-08 Bristol-Myers Squibb Company Oxazolidinones as modulators of mGluR5
US8772300B2 (en) 2011-04-19 2014-07-08 Hoffmann-La Roche Inc. Phenyl or pyridinyl-ethynyl derivatives
UA110378C2 (en) 2011-04-26 2015-12-25 Hoffmann La Roche Etynilni derivative as positive allosteric modulators mglur5
MX2013011107A (es) 2011-04-26 2013-10-17 Hoffmann La Roche Derivados de pirazolidin-3-ona.
US20130123254A1 (en) 2011-09-30 2013-05-16 Barbara Biemans Pharmaceutically acceptable mglur5 positive allosteric modulators and their methods of identification
UA110995C2 (uk) 2011-10-07 2016-03-10 Ф. Хоффманн-Ля Рош Аг Етинільні похідні як модулятори метаботропного глутаматного рецептора
UA110862C2 (uk) 2011-10-07 2016-02-25 Ф. Хоффманн-Ля Рош Аг Похідні етинілу як алостеричні модулятори метаботропного рецептора глутамату mglur 5
LT2875000T (lt) * 2012-07-17 2016-11-10 F.Hoffmann-La Roche Ag Ariletinilo dariniai
UA113223C2 (xx) 2012-08-13 2016-12-26 Арилетинілпіримідини
CA2885382A1 (en) * 2012-09-27 2014-04-17 F. Hoffmann-La Roche Ag Arylethynyl derivatives
EA026941B1 (ru) * 2012-10-18 2017-06-30 Ф. Хоффманн-Ля Рош Аг ПРОИЗВОДНЫЕ ЭТИНИЛА В КАЧЕСТВЕ МОДУЛЯТОРОВ АКТИВНОСТИ РЕЦЕПТОРА mGluR5
BR112015006454A8 (pt) * 2012-10-18 2019-08-20 Hoffmann La Roche derivados de etinila como moduladores de atividade de receptor de mglur5
UA116023C2 (uk) * 2013-07-08 2018-01-25 Ф. Хоффманн-Ля Рош Аг Етинільні похідні як антагоністи метаботропного глутаматного рецептора
MA39305A3 (fr) 2014-02-25 2018-05-31 Hoffmann La Roche Dérivés d'éthynyle

Also Published As

Publication number Publication date
KR20180004821A (ko) 2018-01-12
JP6603334B2 (ja) 2019-11-06
BR112017023894A2 (pt) 2018-07-17
TWI589571B (zh) 2017-07-01
HK1249096A1 (zh) 2018-10-26
SI3303316T1 (sl) 2020-07-31
HUE048867T2 (hu) 2020-08-28
EP3303316A1 (en) 2018-04-11
CA2985301A1 (en) 2016-12-08
CL2017002969A1 (es) 2018-04-13
US20180086680A1 (en) 2018-03-29
RS60199B1 (sr) 2020-06-30
CN107849006A (zh) 2018-03-27
AU2016273751A1 (en) 2017-11-16
PL3303316T3 (pl) 2020-06-29
IL255367A0 (en) 2017-12-31
LT3303316T (lt) 2020-05-11
PT3303316T (pt) 2020-04-27
US11059766B2 (en) 2021-07-13
HRP20200638T1 (hr) 2020-07-10
ES2786673T3 (es) 2020-10-13
US20210300844A1 (en) 2021-09-30
UA120309C2 (uk) 2019-11-11
AR104842A1 (es) 2017-08-16
CN107849006B (zh) 2020-11-13
EP3303316B1 (en) 2020-01-29
KR102035048B1 (ko) 2019-10-22
WO2016193234A1 (en) 2016-12-08
AU2016273751B2 (en) 2020-04-02
MX2017015043A (es) 2018-02-26
JP2018517695A (ja) 2018-07-05
MA42508B1 (fr) 2020-05-29
IL255367B (en) 2021-02-28
PH12017502128A1 (en) 2018-05-28
CO2017012260A2 (es) 2018-03-28
PE20180358A1 (es) 2018-02-21
TW201708204A (zh) 2017-03-01
DK3303316T3 (da) 2020-04-27
RU2712633C1 (ru) 2020-01-30

Similar Documents

Publication Publication Date Title
DOP2019000168A (es) Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer
CL2020001097A1 (es) Derivados de piridincarbonilo y usos terapéuticos de los mismos como inhibidores de trpc6.
CL2011001263A1 (es) Compuestos derivados de pirimidinonas opcionalmente sustituidas; composicion farmaceutica que los comprende; y su uso como inhibidores de fosfodiesterasa 1 (pde1) para el tratamiento de enfermedades que involucran trastornos de la trayectoria intracelular del receptor de dopamina d1 como parkinson, alzheimer, depresion, enfermedad bipolar, hipertension, glaucoma.
DOP2013000181A (es) Moduladores del receptor de glucagon
CO2017000222A2 (es) Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble
UY32574A (es) Antagonistas del receptor cxcr3
AR093042A1 (es) Derivados de etinilo
CL2019002900A1 (es) Análogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton.
CL2021000844A1 (es) Compuestos de indolinona para uso como inhibidores de map4k1
NI201900080A (es) Moduladores del receptor de estrógeno
CY1122321T1 (el) Παραγωγα φθοροϊνδολιου ως θετικοι αλλοστερικοι διαμορφωτες του μουσκαρινικου υποδοχεα μ1
CO2017003305A2 (es) Derivados de la amida del ácido 2-[piridin-3-il]-2,3-dihidro-benzo[1,4]dioxin-5-carboxílico o del 2-[piridin-3-il]-2,3-dihidro-benzo[1,4]dioxin-5-carbonitrilo como inhibidores de aldosterona sintasa
AR096824A1 (es) Derivados de etinilo
CY1124301T1 (el) Ενωσεις ινδαζολης για χρηση σε κακωσεις του τενοντα ή/και των συνδεσμων
CO6541592A2 (es) Tiazoles biciclicos como moduladores alostericos de receptores de mglur5
AR093029A1 (es) Derivados de etilino
AR093043A1 (es) Derivados de etinilo
SV2011003896A (es) Pirrolidinas
CO7180198A2 (es) Ariletinilo pirimidinas
CO2017012260A2 (es) Derivados de etinilo
CO6541615A2 (es) Tiazoles bicíclicos como moduladores alostéricos de receptores mglur5
TH1701007172A (th) อนุพันธ์เอทธินิล
CU20130106A7 (es) Moduladores del receptor de glucagón